dc.contributor.author | Wu, Che-Yuan | |
dc.contributor.author | Xiong, Lisa Y. | |
dc.contributor.author | Ouk, Michael | |
dc.contributor.author | Rabin, Jennifer S. | |
dc.contributor.author | Herrmann, Nathan | |
dc.contributor.author | Lanctôt, Krista L. | |
dc.contributor.author | Kapral, Moira K. | |
dc.contributor.author | Law, Marcus | |
dc.contributor.author | Cogo Moreira, Hugo | |
dc.contributor.author | Edwards, Jodi D. | |
dc.contributor.author | Swardfager, Walter | |
dc.date.accessioned | 2023-04-05T09:28:19Z | |
dc.date.available | 2023-04-05T09:28:19Z | |
dc.date.created | 2023-01-05T14:32:56Z | |
dc.date.issued | 2022 | |
dc.identifier.citation | Alzheimer's and Dementia: Translational Research and Clinical Interventions. 2022, 8 (1), Artikkel e12243. | en_US |
dc.identifier.issn | 2352-8737 | |
dc.identifier.uri | https://hdl.handle.net/11250/3062203 | |
dc.description.abstract | Introduction
Studies suggest associations between proton pump inhibitors (PPIs) and dementia risk; however, many neither considered histamine-2 receptor antagonists (H2RAs) nor baseline cognitive status.
Methods
Participants (National Alzheimer's Coordinating Center Database; 2005–2021) using a PPI or H2RA were compared. Covariate-adjusted Cox regression was used to estimate hazard ratios (HR) for progression from normal cognition to mild cognitive impairment (MCI), and from MCI to dementia over 5 years. In a propensity-score–matched subsample of mild–moderate Alzheimer's disease (AD), mixed-effects negative binomial regression was used to estimate decline in delayed recall memory.
Results
Compared to PPI, H2RA use was associated with earlier progression from MCI to dementia (HR = 1.40 [1.09–1.81]; n = 1701), and with faster memory decline in AD over time (rate ratio = 0.76 [0.64–0.92]; n = 628), but not with progression from normal cognition to MCI (HR = 0.94 [0.71–1.24]; n = 2784).
Discussion
Compared to PPIs, H2RAs were associated with cognitive decline, specifically among people with pre-existing cognitive impairment. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Wiley | en_US |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/deed.no | * |
dc.title | Gastric acid suppressants and cognitive decline in people with or without cognitive impairment | en_US |
dc.type | Peer reviewed | en_US |
dc.type | Journal article | en_US |
dc.description.version | publishedVersion | en_US |
dc.subject.nsi | VDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Psykiatri, barnepsykiatri: 757 | en_US |
dc.subject.nsi | VDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Nevrologi: 752 | en_US |
dc.source.volume | 8 | en_US |
dc.source.journal | Alzheimer's and Dementia: Translational Research and Clinical Interventions | en_US |
dc.source.issue | 1 | en_US |
dc.identifier.doi | 10.1002/trc2.12243 | |
dc.identifier.cristin | 2101418 | |
dc.source.articlenumber | e12243 | en_US |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |